Tracery Opthalmics is a health technology company developing a novel ocular imaging acquisition method and large data analytics platform with the ultimate goal of developing superior biomarkers and measures of disease. Dr. Shelley Boyd, President and CSO delivered the pitch and took home the prize.
Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit membership based organization that is Ontario’s leading advocate for the health science industry, announced today that Ontario health science companies that have participated in its Capital Access Advisory Program (CAAP®) have raised more than $109 Million since the CAAP program launched in 2013.
OBIO CAAP® is a unique, industry-led initiative that provides selected high-potential Ontario health science companies with mentoring, strategic guidance and access to an expansive network of health science industry experts and investors to enhance the ability of OBIO CAAP companies to secure financing.
Iris Technologies, whose E-Paper screen technology reduces the negative health repercussions of using LCD screens for individuals recovering from a concussion, released a powerful testimonial video. David Goldband describes his experience with the product, and how it helped in his recovery.
On November 27, 2017, OBIO hosted keynote speaker Dr. Edward Abrahams, President of the Personalized Medicine Coalition, at its 9th Annual Public Meeting at Norton Rose Fulbright LLP and launched OBIO's latest report, "Bridging the Talent Gap"
Springboard’s Health Innovation Hub is a program for women-led life science and digital health companies seeking seed and growth funding and expert connections. The program runs in two tracks: Life Science and Digital Health.
Selected companies will be matched with a team of relevant, targeted advisors and participate in several in-person and virtual workshops and presentation sessions throughout the year that provide exposure to influencers, active investors, and potential strategic partners.
TORONTO, ON Thornhill and Rostrum celebrate the finalization of a Technology Development Agreement which includes the licensing of certain Thornhill IP and an investment by Rostrum into Thornhill. This agreement is aimed to further Rostrum’s development of its Pulmonary Health Monitoring during ventilation, in ICU, OR and ER applications while supporting Thornhill’s commercialization efforts of their own innovative products.
TORONTO, ON KalGene Pharmaceuticals announced the closing of a Series A financing to support the advancement of its lead Alzheimer's therapeutic program. The syndicated investment was led by Lumira Capital and included participation from Anges Québec, Anges Québec Capital, Accel-Rx Health Sciences Accelerator and a number of Canadian family offices. In addition to the equity financing the company has also received significant financial support from leading Foundations focused on neurodegenerative diseases. Proceeds from these combined funding sources will support the development of KalGene's lead Alzheimer's therapeutic candidate.